New York, NY and Franklin Lakes, NJ (January 19, 2010) – The Juvenile Diabetes Research Foundation (JDRF) and BD (Becton, Dickinson and Company) (NYSE:BDX) announced today an innovative program aimed at improving the treatment of type 1 diabetes by developing novel insulin delivery products to enhance the use of insulin pumps.

Through the program, JDRF will support BD’s research and development of new products that deliver insulin from a pump to a patient in either an infusion set or patch-pump configuration. Research indicates that there are significant opportunities to enhance pump therapy by improving convenience as well as minimizing pain, kinking, occlusions and site infections. An additional goal of the program is improving the speed at which insulin works. These enhancements are intended to improve how people with diabetes control their insulin therapy and have a positive impact on their overall level of glycemic control.

Read the full story.

The national JDRF has an entire site with more information about the artificial pancreas project.